Table 1.

Base Case Input Parameters for a Model Assessing the Clinical Impact and Cost-effectiveness of Measles-Mumps-Rubella (MMR) Vaccination During Pretravel Health Encounter (PHE)

Variable		Base Case	No. (Range)
Demographics [12]
Median age, years (IQR)		30	(22–41)
Female (%)		56
Baseline MMR vaccination status [6, 12]
2 MMR vaccinations (%)a		84
1 MMR vaccination (%)		9
0 MMR vaccinations (%)		7	(0–90)
Risk of measles exposure during travel; see Supplementary Material (exposures per 10M travelers) [15]
All international travel		237	(10-10000)
By continent
Travel to North America		19
Travel to Europe		434
Travel to Africa		681
Travel to Asia		975
Risk of measles exposure during travel; see Supplementary Material (exposures per 10M travelers) [15]
By hot spot
Travel to the Philippines, 2014		1940
Travel to India, 2011		2490
Travel to Poland, 2013		3340
Travel to Pakistan, 2013		6750
	Number of MMR vaccinations at baseline
	2	1	0
Measles infection, if exposed (%) [1, 7]	3 (0–10)	7 (3–90)	90 (0–90)
US-acquired cases, if infected (n) [3, 7]	0 (0–20)	4 (0–382)	4 (0–382)
Contacts, if infected (n) [4]	200 (0–2000)	1500 (0–12000)	1500 (0–12000)
Costs of PHE ($) [16, 17]b, c
First visit	7 (5–300)	95 (5–300)	95 (5–300)
Second visit	—	—	90 (5–300)
Costs (US$)
Per imported measles case [7, 18–20]c		13200	(11600–46800)
Per US-acquired measles case [7, 18–20]c		4800	(2500–14100)
Per contact [4, 21],c		550	(370–850)

Abbreviations: IQR, interquartile range; MMR, measles-mumps-rubella; PHE, pretravel health encounter

^aOr alternate evidence of immunity.

^bProrated for percentage of visit dedicated to measles, and includes cost of MMR vaccination and administration when given, as well as time lost from work.

^cCosts include time lost from work.